Efficacy and safety of vesatolimod in chronic hepatitis B: A systematic review and meta-analysis

医学 内科学 乙型肝炎表面抗原 肝细胞癌 乙型肝炎 HBeAg 随机对照试验 梅德林 荟萃分析 批判性评价 临床试验 乙型肝炎病毒 胃肠病学 免疫学 替代医学 病理 病毒 政治学 法学
作者
Ibrahim Omer,Noorah Abuthiyab,Basil Al‐Omari,Tala Aletani,Manar Betar,Nura Al Zaid,Alqassem Y. Hakami
出处
期刊:Medicine [Wolters Kluwer]
卷期号:102 (16): e33609-e33609 被引量:4
标识
DOI:10.1097/md.0000000000033609
摘要

BACKGROUND: Vesatolimod is a toll-like receptor (TLR) agonist that is thought to suppress chronic hepatitis B (HBV) infection. This systematic review aimed to assess the safety and efficacy of vesatolimod in treating chronic hepatitis B. METHODS: We included randomized clinical trials (RCTs) that assessed vesatolimod in patients with hepatitis B infection without hepatocellular carcinoma or liver transplantation and with reported levels of hepatitis B surface antigen (HBsAg) or liver transaminases post-intervention. We searched MEDLINE, SCOPUS, Springer, Google Scholar, ClinicalTrials.gov, and Cochrane Central Register of Clinical Trials for all related articles during May 2022. Two independent authors screened articles for inclusion, and discrepancies were resolved by consensus and a third reviewer. Two independent reviewers assessed studies included in this systematic review using the Critical Appraisal Skills Programme checklist for RCTs. RESULTS AND CONCLUSION: Only 4 were considered eligible from 391 articles identified through our search. All eligible studies did not report any clinically significant outcomes following the use of vesatolimod, as evidenced by the persistence of HBsAg. However, vesatolimod was associated with induction of interferon-stimulated genes (ISGs) and only mild side effects, warranting further studies to evaluate its potential for future use as a safe, tolerable anti-HBV medication. No significant differences were noted amongst trials included in either of Vesatolimod doses (Vesatolimod 1 mg, RR = 0.99, 95% CI 0.76-1.30, P = .95, I2 = 0%; Vesatolimod 2 mg, RR = 1.06, 95% CI 0.82-1.37, P = .66, I2 = 0%; Vesatolimod 4 mg, RR = 1.06, 95% CI 0.82-1.37, P = .66, I2 = 0%;), further suggesting its comparable safety in comparison to oral antiviral agents.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
顾矜的应助被科研通管家采纳,获得10
刚刚
英姑的应助被科研通管家采纳,获得10
刚刚
刚刚
刚刚
我是老大的应助被科研通管家采纳,获得10
刚刚
完美世界的应助被科研通管家采纳,获得10
刚刚
大模型的应助被科研通管家采纳,获得10
刚刚
xiang完成签到,获得积分10
1秒前
小小的应助被科研通管家采纳,获得150
1秒前
Jasper的应助被科研通管家采纳,获得10
1秒前
1秒前
molihuakai的应助被科研通管家采纳,获得10
1秒前
1秒前
大个的应助被鸭鸭采纳,获得10
1秒前
1秒前
Eyoung完成签到 ,获得积分10
2秒前
丘山完成签到 ,获得积分10
2秒前
英俊的铭的应助被chen采纳,获得10
3秒前
好多炉发布了新的文献求助10
3秒前
完美世界的应助被jolly0304采纳,获得10
4秒前
4秒前
Cyuan发布了新的文献求助10
5秒前
12发布了新的文献求助10
5秒前
e00ec发布了新的文献求助10
5秒前
朴实流沙发布了新的文献求助10
6秒前
6秒前
6秒前
爆米花的应助被hugo采纳,获得10
8秒前
Ava的应助被ayzzdbr采纳,获得10
8秒前
Jasper的应助被高兴凝安采纳,获得10
9秒前
zzz完成签到,获得积分10
9秒前
10秒前
make217发布了新的文献求助10
10秒前
Kia发布了新的文献求助30
10秒前
精明的小熊猫完成签到,获得积分10
11秒前
11秒前
11秒前
12秒前
嘻嘻哈哈的应助被zzz采纳,获得10
15秒前
好多炉完成签到 ,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175262
求助须知:如何正确求助?哪些是违规求助? 9567017
关于积分的说明 21789663
捐赠科研通 7769695
什么是DOI,文献DOI怎么找? 3431840
关于科研通互助平台的介绍 2556124
邀请新用户注册赠送积分活动 2477241